Description: Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company develops BRII-778 and BRII-732, which are in phase I clinical trials for the treatment of HIV patients; BRII-179 and BRII-835, which are in Phase 2 to evaluate the combination of these two HBV mechanisms for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 1b/2a; BRII-835, which has completed Phase-2 for patients with chronic HBV infection; and Amubarvimab/romlusevimab combination therapy for the treatment of COVID-19. It also develops BRII-296 for the treatment of PPD; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for the treatment of MDR/XDR tuberculosis and non-tuberculosis mycobacteria. The company was incorporated in 2017 and is based in Beijing, China.
Home Page: www.briibio.com
Building 7
Beijing,
100192
China
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Zhi Hong Ph.D. | Co-founder, Exec. Chairman & CEO |
| Dr. Ankang Li C.F.A., J.D., Ph.D. | Chief Financial & Strategy Officer, Company Sec. and Exec. Director |
| Dr. Eleanor de Groot Ph.D. | Chief Technology Officer |
| Ms. Karen Del Barrio Neuendorff | Chief People Officer & Head of HR |
| Mr. Coy Stout | Head of Patient Advocacy |
| Dr. Li Yan M.D., Ph.D. | Chief Medical Officer |
| Dr. Lianhong Xu Ph.D. | Head of Discovery |
| Dr. Qing Zhu Ph.D. | Head of China R&D |
| Dr. David Margolis M.D., M.P.H. | VP & Head of Infectious Diseases Therapy Area |
| Dr. Susannah Cantrell Ph.D. | Chief Bus. Officer |
Exchange: HK
Country: HK
Currency: Hong Kong Dollar (HK$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.678 |
| Price-to-Sales TTM: | 80.3971 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 123 |